70.34 USD
+1.37 (+1.99%)
70 USD
-0.34 (-0.48%)
We assign a fundamental rating of 7 out of 10 to HALO. HALO was compared to 533 industry peers in the Biotechnology industry. While HALO has a great profitability rating, there are some minor concerns on its financial health. HALO is growing strongly while it also seems undervalued. This is an interesting combination These ratings would make HALO suitable for value and growth investing!
1. Profitability
1.1 Basic Checks
HALO had positive earnings in the past year.
In the past year HALO had a positive cash flow from operations.
In the past 5 years HALO has always been profitable.
In the past 5 years HALO always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of HALO (26.81%) is better than 97.56% of its industry peers.
Looking at the Return On Equity, with a value of 118.17%, HALO belongs to the top of the industry, outperforming 99.44% of the companies in the same industry.
HALO has a better Return On Invested Capital (42.77%) than 99.44% of its industry peers.
The Average Return On Invested Capital over the past 3 years for HALO is in line with the industry average of 19.19%.
The 3 year average ROIC (17.81%) for HALO is below the current ROIC(42.77%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 26.81% | ||
| ROE | 118.17% | ||
| ROIC | 42.77% |
ROA(3y)16.25%
ROA(5y)21.49%
ROE(3y)192.36%
ROE(5y)173.4%
ROIC(3y)17.81%
ROIC(5y)29.79%
1.3 Margins
The Profit Margin of HALO (47.91%) is better than 98.50% of its industry peers.
In the last couple of years the Profit Margin of HALO has declined.
HALO has a Operating Margin of 59.33%. This is amongst the best in the industry. HALO outperforms 99.81% of its industry peers.
HALO's Operating Margin has declined in the last couple of years.
HALO's Gross Margin of 84.55% is amongst the best of the industry. HALO outperforms 87.05% of its industry peers.
HALO's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 59.33% | ||
| PM (TTM) | 47.91% | ||
| GM | 84.55% |
OM growth 3Y-4.44%
OM growth 5YN/A
PM growth 3Y-21.62%
PM growth 5YN/A
GM growth 3Y1.07%
GM growth 5Y1.9%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so HALO is creating value.
The number of shares outstanding for HALO has been reduced compared to 1 year ago.
The number of shares outstanding for HALO has been reduced compared to 5 years ago.
Compared to 1 year ago, HALO has an improved debt to assets ratio.
2.2 Solvency
HALO has an Altman-Z score of 5.06. This indicates that HALO is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of HALO (5.06) is better than 74.86% of its industry peers.
HALO has a debt to FCF ratio of 2.51. This is a good value and a sign of high solvency as HALO would need 2.51 years to pay back of all of its debts.
HALO's Debt to FCF ratio of 2.51 is amongst the best of the industry. HALO outperforms 93.25% of its industry peers.
HALO has a Debt/Equity ratio of 1.59. This is a high value indicating a heavy dependency on external financing.
HALO has a worse Debt to Equity ratio (1.59) than 79.74% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.59 | ||
| Debt/FCF | 2.51 | ||
| Altman-Z | 5.06 |
ROIC/WACC5.41
WACC7.9%
2.3 Liquidity
A Current Ratio of 1.59 indicates that HALO should not have too much problems paying its short term obligations.
The Current ratio of HALO (1.59) is worse than 81.24% of its industry peers.
HALO has a Quick Ratio of 1.37. This is a normal value and indicates that HALO is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.37, HALO is not doing good in the industry: 82.55% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.59 | ||
| Quick Ratio | 1.37 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 48.55% over the past year.
HALO shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 30.12% yearly.
HALO shows a strong growth in Revenue. In the last year, the Revenue has grown by 31.19%.
Measured over the past years, HALO shows a very strong growth in Revenue. The Revenue has been growing by 38.95% on average per year.
EPS 1Y (TTM)48.55%
EPS 3Y30.12%
EPS 5YN/A
EPS Q2Q%35.43%
Revenue 1Y (TTM)31.19%
Revenue growth 3Y31.82%
Revenue growth 5Y38.95%
Sales Q2Q%22.12%
3.2 Future
The Earnings Per Share is expected to grow by 18.25% on average over the next years. This is quite good.
Based on estimates for the next years, HALO will show a quite strong growth in Revenue. The Revenue will grow by 13.85% on average per year.
EPS Next Y48.46%
EPS Next 2Y38.68%
EPS Next 3Y32.65%
EPS Next 5Y18.25%
Revenue Next Year31.48%
Revenue Next 2Y27.84%
Revenue Next 3Y24.03%
Revenue Next 5Y13.85%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 12.49, HALO is valued correctly.
Based on the Price/Earnings ratio, HALO is valued cheaper than 96.44% of the companies in the same industry.
HALO is valuated cheaply when we compare the Price/Earnings ratio to 25.45, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 8.65, the valuation of HALO can be described as reasonable.
HALO's Price/Forward Earnings ratio is rather cheap when compared to the industry. HALO is cheaper than 97.94% of the companies in the same industry.
HALO is valuated cheaply when we compare the Price/Forward Earnings ratio to 34.46, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.49 | ||
| Fwd PE | 8.65 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, HALO is valued cheaply inside the industry as 96.44% of the companies are valued more expensively.
HALO's Price/Free Cash Flow ratio is rather cheap when compared to the industry. HALO is cheaper than 97.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 13.66 | ||
| EV/EBITDA | 10.49 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
HALO has an outstanding profitability rating, which may justify a higher PE ratio.
HALO's earnings are expected to grow with 32.65% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.26
PEG (5Y)N/A
EPS Next 2Y38.68%
EPS Next 3Y32.65%
5. Dividend
5.1 Amount
No dividends for HALO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
70.34
+1.37 (+1.99%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners102.63%
Inst Owner Change15.62%
Ins Owners0.85%
Ins Owner Change-1.06%
Market Cap8.23B
Revenue(TTM)1.24B
Net Income(TTM)595.49M
Analysts76.25
Price Target77.18 (9.72%)
Short Float %9.78%
Short Ratio5.12
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.41%
Min EPS beat(2)3.56%
Max EPS beat(2)19.26%
EPS beat(4)4
Avg EPS beat(4)11.06%
Min EPS beat(4)3.56%
Max EPS beat(4)19.26%
EPS beat(8)7
Avg EPS beat(8)12.2%
EPS beat(12)10
Avg EPS beat(12)9.54%
EPS beat(16)13
Avg EPS beat(16)9.68%
Revenue beat(2)2
Avg Revenue beat(2)6.93%
Min Revenue beat(2)2.18%
Max Revenue beat(2)11.69%
Revenue beat(4)4
Avg Revenue beat(4)7.01%
Min Revenue beat(4)1.36%
Max Revenue beat(4)12.81%
Revenue beat(8)6
Avg Revenue beat(8)5.71%
Revenue beat(12)7
Avg Revenue beat(12)2.94%
Revenue beat(16)9
Avg Revenue beat(16)2.47%
PT rev (1m)1.4%
PT rev (3m)13.57%
EPS NQ rev (1m)2.21%
EPS NQ rev (3m)3.32%
EPS NY rev (1m)-0.14%
EPS NY rev (3m)11.94%
Revenue NQ rev (1m)0.5%
Revenue NQ rev (3m)0.42%
Revenue NY rev (1m)-0.07%
Revenue NY rev (3m)5.66%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.49 | ||
| Fwd PE | 8.65 | ||
| P/S | 6.62 | ||
| P/FCF | 13.66 | ||
| P/OCF | 13.47 | ||
| P/B | 16.33 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.49 |
EPS(TTM)5.63
EY8%
EPS(NY)8.14
Fwd EY11.57%
FCF(TTM)5.15
FCFY7.32%
OCF(TTM)5.22
OCFY7.43%
SpS10.63
BVpS4.31
TBVpS-2.24
PEG (NY)0.26
PEG (5Y)N/A
Graham Number23.36
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 26.81% | ||
| ROE | 118.17% | ||
| ROCE | 53.28% | ||
| ROIC | 42.77% | ||
| ROICexc | 86.79% | ||
| ROICexgc | N/A | ||
| OM | 59.33% | ||
| PM (TTM) | 47.91% | ||
| GM | 84.55% | ||
| FCFM | 48.47% |
ROA(3y)16.25%
ROA(5y)21.49%
ROE(3y)192.36%
ROE(5y)173.4%
ROIC(3y)17.81%
ROIC(5y)29.79%
ROICexc(3y)23.94%
ROICexc(5y)N/A
ROICexgc(3y)71.73%
ROICexgc(5y)N/A
ROCE(3y)22.19%
ROCE(5y)37.11%
ROICexgc growth 3Y-1.13%
ROICexgc growth 5YN/A
ROICexc growth 3Y-28.16%
ROICexc growth 5YN/A
OM growth 3Y-4.44%
OM growth 5YN/A
PM growth 3Y-21.62%
PM growth 5YN/A
GM growth 3Y1.07%
GM growth 5Y1.9%
F-Score8
Asset Turnover0.56
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.59 | ||
| Debt/FCF | 2.51 | ||
| Debt/EBITDA | 0.98 | ||
| Cap/Depr | 10.51% | ||
| Cap/Sales | 0.69% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 74.59% | ||
| Profit Quality | 101.16% | ||
| Current Ratio | 1.59 | ||
| Quick Ratio | 1.37 | ||
| Altman-Z | 5.06 |
F-Score8
WACC7.9%
ROIC/WACC5.41
Cap/Depr(3y)13.62%
Cap/Depr(5y)33.32%
Cap/Sales(3y)1.21%
Cap/Sales(5y)0.98%
Profit Quality(3y)118.15%
Profit Quality(5y)93.9%
High Growth Momentum
Growth
EPS 1Y (TTM)48.55%
EPS 3Y30.12%
EPS 5YN/A
EPS Q2Q%35.43%
EPS Next Y48.46%
EPS Next 2Y38.68%
EPS Next 3Y32.65%
EPS Next 5Y18.25%
Revenue 1Y (TTM)31.19%
Revenue growth 3Y31.82%
Revenue growth 5Y38.95%
Sales Q2Q%22.12%
Revenue Next Year31.48%
Revenue Next 2Y27.84%
Revenue Next 3Y24.03%
Revenue Next 5Y13.85%
EBIT growth 1Y54.59%
EBIT growth 3Y25.97%
EBIT growth 5YN/A
EBIT Next Year61.62%
EBIT Next 3Y39.07%
EBIT Next 5Y15.57%
FCF growth 1Y70.36%
FCF growth 3Y16.28%
FCF growth 5YN/A
OCF growth 1Y65.76%
OCF growth 3Y16.96%
OCF growth 5YN/A
HALOZYME THERAPEUTICS INC / HALO FAQ
Can you provide the ChartMill fundamental rating for HALOZYME THERAPEUTICS INC?
ChartMill assigns a fundamental rating of 7 / 10 to HALO.
What is the valuation status for HALO stock?
ChartMill assigns a valuation rating of 9 / 10 to HALOZYME THERAPEUTICS INC (HALO). This can be considered as Undervalued.
Can you provide the profitability details for HALOZYME THERAPEUTICS INC?
HALOZYME THERAPEUTICS INC (HALO) has a profitability rating of 8 / 10.
What is the valuation of HALOZYME THERAPEUTICS INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for HALOZYME THERAPEUTICS INC (HALO) is 12.49 and the Price/Book (PB) ratio is 16.33.
How financially healthy is HALOZYME THERAPEUTICS INC?
The financial health rating of HALOZYME THERAPEUTICS INC (HALO) is 6 / 10.